# CJC-1295 / Ipamorelin: Research Overview — Biotide Peptides > A literature summary of CJC-1295 / Ipamorelin, the lead Growth Hormone Axis research combination: dual-receptor synergy mechanism, sustained GH/IGF-1 pharmacodynamics, safety signals and regulatory status. A GHRH analogue and a selective ghrelin-receptor agonist studied together for supra-additive GH release — the research case for co-stimulating two independent pituitary pathways. ## The short version CJC-1295 / Ipamorelin is a two-peptide research combination. **CJC-1295** is a long-acting analogue of growth-hormone-releasing hormone (GHRH), the pituitary's natural "make more GH" signal. **Ipamorelin** is a synthetic pentapeptide that activates a second, independent receptor on the same pituitary cells — the ghrelin receptor (GHS-R1a). Because the two arms use different molecular switches, co-stimulating them produces a GH pulse meaningfully larger than either peptide alone, which is the mechanistic rationale for the combination [5][7]. The honest assessment: a single subcutaneous dose of CJC-1295 raised GH two- to ten-fold for six or more days in healthy adults [3], and ipamorelin added a selective GH pulse without raising cortisol or ACTH even at large doses [6]. But the fixed CJC-1295 + ipamorelin *combination* has never been evaluated in a controlled clinical trial — its profile is inferred entirely from separate-component studies and general GHRH+GHRP synergy work [2]. Neither compound is FDA-approved for any human indication. This page summarizes what the literature shows; it lists no dose and gives no medical advice. ## What it is CJC-1295 is a tetrasubstituted analogue of the first 29 residues of human growth-hormone-releasing factor, hGRF(1-29)NH2. Four amino-acid substitutions stabilize the alpha-helix and block enzymatic breakdown. In the **DAC (Drug Affinity Complex)** variant, a C-terminal lysine carries a maleimidopropionyl linker that undergoes Michael addition with the free thiol on Cys34 of circulating serum albumin, forming a covalent peptide-albumin conjugate that extends the half-life toward albumin's own multi-day duration [4]. The **no-DAC** form (also called Modified GRF 1-29) keeps the four substitutions but lacks this albumin-binding chemistry and is therefore short-acting. Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, with D-configured residues conferring protease resistance. It is classified as a selective growth hormone secretagogue because, unlike earlier growth-hormone-releasing peptides, it activates GHS-R1a without meaningfully raising ACTH, cortisol, or prolactin [6]. The combination is sold as a research chemical under various names including "CJC-1295 with DAC + Ipamorelin" and "GHRH + GHRP stack"; it is not an approved pharmaceutical product. ## How it works The two components act through mechanistically distinct and complementary pathways on pituitary somatotroph cells. **CJC-1295** binds the GHRH receptor (a class-B GPCR), activating the Gs/cAMP/PKA cascade that drives GH synthesis and release. In the DAC form, covalent albumin binding in rat plasma produced approximately a four-fold increase in GH area under the curve over two hours versus plain hGRF(1-29), with detectable albumin-bound peptide in plasma beyond 72 hours [4]. In healthy adults, this translated to multi-day GH and IGF-1 elevation per dose [3]. **Ipamorelin** binds GHS-R1a (the ghrelin receptor) on the same pituitary cells, raising intracellular calcium via Gq rather than cAMP, and triggering a discrete GH pulse. Because this is a Gq/calcium pathway rather than a Gs/cAMP pathway, the two arms do not simply add — they converge on GH release through independent intracellular machinery. **Synergy.** In transfected HeLa cells co-expressing both the GHRH receptor and GHS-R1a, co-activation produced a cAMP response approximately twice that of GHRH-receptor activation alone, demonstrating direct receptor-level cross-talk [5]. In healthy adult men, submaximal GHRP + GHRH doses each too small to produce maximal GH release together produced supra-additive GH output [7]. This dual-receptor convergence is the primary scientific rationale for studying the combination. ## What the research shows *GHRH-analogue class human data.* A 2026 meta-analysis of five RCTs of tesamorelin — a closely related GHRH analogue — found significant reductions in visceral adipose tissue (mean difference −27.71 cm²) and hepatic fat (−4.28%), increased lean body mass (+1.42 kg) and IGF-1, with no serious adverse events or glucose perturbation [1]. This is the freshest high-quality human evidence for GHRH-analogue stimulation of the GH/IGF-1 axis, providing read-across context for the GHRH arm of the combination. *CJC-1295 DAC pharmacodynamics.* A single subcutaneous dose (30 or 60 micrograms per kilogram) in healthy adults aged 21–61 produced 2- to 10-fold increases in mean plasma GH for 6 or more days and 1.5- to 3-fold increases in IGF-1 for 9–11 days; after multiple doses, IGF-1 remained above baseline up to 28 days, with an estimated CJC-1295 half-life of 5.8–8.1 days [3]. *Albumin-binding chemistry.* In Sprague-Dawley rats, the DAC linker on CJC-1295 produced roughly a four-fold increase in GH AUC over two hours versus the unmodified hGRF(1-29) and detectable albumin-bound peptide beyond 72 hours — the mechanism that gives the DAC form its extended pharmacodynamic profile [4]. *Receptor cross-talk.* Co-activation of cloned GHRH and GHS receptors in HeLa cells produced a cAMP response approximately double that of the GHRH receptor alone, providing a receptor-level mechanistic explanation for the combination synergy [5]. *Ipamorelin selectivity.* Unlike GHRP-6 and GHRP-2, ipamorelin did not raise ACTH or cortisol above GHRH-stimulated levels at doses more than 200 times its GH ED50 in swine, while matching GHRP-6's GH efficacy — the founding characterization of ipamorelin as the first selective GH secretagogue [6]. *Human GHRP + GHRH synergy.* In eighteen healthy adult men, submaximal doses of GHRP (0.1 and 0.3 micrograms per kilogram) combined with GHRH (1 microgram per kilogram) stimulated GH release synergistically through independent mechanisms — the foundational human evidence base for combining a GHRP with a GHRH analogue [7]. *Safety class review.* A review of GH secretagogues found them generally well tolerated, with the chief safety concern being increased blood glucose from decreased insulin sensitivity; long-term data on cancer incidence and mortality remain outstanding [2]. ## Reported effects, cautions & safety **Community-reported effects (anecdotal, not clinical evidence).** Research-use community accounts most consistently describe: deeper, more restorative sleep and faster workout recovery (both frequently reported); gradual shifts toward leaner body composition over weeks to months, increased appetite particularly in hours after injection, and improvements in skin, nail, and connective-tissue feel (all occasionally reported). Adverse effects include injection-site redness, itching, or mild swelling (frequently reported); water retention and puffiness, facial flushing, tingling or carpal-tunnel-like hand symptoms, lethargy or grogginess after dosing, and lightheadedness (all occasionally or sometimes reported). These are anecdotal, unverified, dose and source unknown — not clinical findings. **Cited safety cautions.** The following arise directly from the literature: - *Active or recent malignancy.* GH drives hepatic IGF-1 production; IGF-1 is a well-characterized mitogen. CJC-1295 raised IGF-1 1.5- to 3-fold for 9–11 days per dose in healthy adults [3], and ipamorelin potently releases GH [6]. The theoretical concern is that chronically elevating GH/IGF-1 could accelerate proliferative activity in pre-existing or occult tumors. This is mechanistic reasoning, not an observed event in any trial of the combination. - *Diabetes or impaired glucose tolerance.* GH is a counter-regulatory hormone that reduces peripheral insulin sensitivity. The secretagogue class review identifies increased blood glucose and decreased insulin sensitivity as the chief metabolic concern [2]; the combination, designed to raise GH output, carries that class-level glycemic risk. - *Mismatched pharmacokinetics.* CJC-1295 DAC produces multi-day GH and IGF-1 elevation [3][4], while ipamorelin has a terminal half-life of approximately 2 hours [15]. Pairing a multi-day agent with a short-acting one means the net GH exposure and the intended pulsatile synergy profile are not characterized for any specific protocol. - *Fluid retention, carpal tunnel, joint pain.* GH excess classically causes sodium and water retention, soft-tissue swelling, and arthralgia [2]. The CJC-1295 component is documented to raise GH and IGF-1 substantially for days; these GH-mediated effects are the mechanistically expected nuisances. - *Cardiovascular vulnerability.* Sustained GH-related fluid retention can worsen edema and volume-overload conditions. The secretagogue review notes cardiovascular and fluid-handling as considerations for sustained GH elevation [2]. - *Unknown long-term safety; unverified purity.* Neither component is approved for human use, the fixed combination has never been studied in a controlled human trial, and research-grade material from unregulated suppliers carries no pharmaceutical quality assurance [2]. ## Where it fits in GH-axis research Among the three entries on this desk, CJC-1295 / Ipamorelin is the combined-pharmacology lead — the reason the stack concept exists — while [CJC-1295](/cjc-1295) and [Ipamorelin](/ipamorelin) provide the individual component depth. The combination's story is ultimately a mechanistic inference built from two separate evidence bases and general GHRH+GHRP synergy work in normal men [7]. There are no completed controlled clinical trials of the fixed blend for any indication, which makes this also the clearest example of how far inference can travel from first-principles receptor pharmacology into community practice without the clinical checkpoint. See the [comparison page](/compare) for how the three stack up. ![CJC-1295 and ipamorelin pituitary receptor-binding research illustration](/images/cjc1295-ipamorelin.webp) --- A peer-reviewed briefing on GH-axis research peptides — citations anchored to primary literature, no products, no clinical recommendations.